COM:POSEIDA
Poseida Therapeutics, Inc.
- Stock
Last Close
2.71
22/11 21:00
Market Cap
266.08M
Beta: -
Volume Today
362.56K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | 2.23M - | 2.23M 0% | ||||||
average payables | 2.01M - | 3.89M 93.66% | 2.85M 26.89% | 4.86M 70.84% | 5.59M 15.07% | 2.75M 50.89% | ||
average receivables | 4.54M - | 9.05M 99.14% | ||||||
book value per share | -0.84 - | -2.14 152.92% | -3.76 76.23% | 7.28 293.41% | 2.51 65.51% | 2.61 3.87% | 0.00 99.96% | |
capex per share | -0.01 - | -0.04 606.43% | -0.13 263.12% | -0.47 261.97% | -0.04 90.99% | -0.05 28.86% | -0.00 99.94% | |
capex to depreciation | -0.30 - | -1.86 526.75% | -4.32 131.91% | -6.54 51.28% | -0.58 91.15% | -0.76 31.12% | -0.55 28.02% | |
capex to operating cash flow | 0.01 - | 0.03 281.41% | 0.08 137.07% | 0.15 86.32% | 0.03 82.78% | 0.15 470.61% | 0.03 77.30% | |
capex to revenue | -0.07 - | -84.32 - | -0.03 99.96% | -0.05 57.42% | ||||
cash per share | 0.39 - | 0.85 115.12% | 3.15 272.83% | 8.59 172.30% | 3.32 61.40% | 3.93 18.43% | 0.00 99.94% | |
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | 25.45 - | 50.83 99.75% | ||||||
debt to assets | 0.38 - | 0.42 10.91% | 0.20 53.14% | 0.16 19.45% | 0.23 42.32% | 0.25 11.01% | 0.31 23.64% | |
debt to equity | -0.29 - | -0.25 14.04% | -0.19 21.66% | 0.23 216.17% | 0.39 73.03% | 0.47 20.76% | 0.82 74.11% | |
dividend yield | ||||||||
earnings yield | -0.03 - | -0.08 149.75% | -0.15 88.66% | 0.01 104.09% | 0.01 67.31% | -0.17 1,715.17% | -0.00 99.76% | |
enterprise value | 604.00M - | 540.22M 10.56% | 551.27M 2.05% | 370.24M 32.84% | 278.70M 24.72% | 388.73M 39.48% | 303.06B 77,862.58% | |
enterprise value over ebitda | -28.93 - | -13.28 54.10% | -7.34 44.71% | -2.93K 39,843.31% | -2.29K 21.84% | -6.81 99.70% | -2.34K 34,267.49% | |
ev to operating cash flow | -26.61 - | -14.21 46.60% | -8.56 39.75% | -3.27 61.84% | -2.72 16.81% | -14.52 434.24% | -3.29K 22,546.00% | |
ev to sales | 202.34 - | 8.92K - | 2.98 99.97% | 4.68K 156,976.48% | ||||
free cash flow per share | -0.58 - | -1.09 89.79% | -1.75 60.03% | -3.62 106.71% | -1.69 53.29% | -0.43 74.76% | -0.00 99.75% | |
free cash flow yield | -0.04 - | -0.07 89.79% | -0.11 60.03% | -0.33 189.24% | -0.25 24.76% | -0.08 67.56% | -0.00 99.61% | |
graham net net | -1.09 - | -2.55 133.15% | -4.31 69.29% | 5.55 228.72% | 1.50 72.99% | 1.77 18.11% | 0.00 99.97% | |
graham number | 3.07 - | 7.71 151.33% | 14.05 82.34% | 3.34 76.23% | 2.00 40.15% | 7.22 261.35% | 0.01 99.92% | |
income quality | 1.15 - | 0.86 25.84% | 0.74 13.07% | 0.87 17.35% | 0.82 6.04% | 0.42 49.02% | 0.75 78.51% | |
intangibles to total assets | 0.27 - | 0.12 54.19% | 0.04 69.31% | 0.01 60.43% | 0.02 37.94% | 0.02 23.46% | 0.02 28.46% | |
interest coverage | -35.25 - | -23.38 33.67% | -24.07 2.97% | -36.09 49.94% | -42.11 16.67% | -9.41 77.65% | 14.94 258.71% | |
interest debt per share | 0.26 - | 0.58 124.94% | 0.82 41.57% | 1.65 100.28% | 0.98 40.32% | 1.32 34.43% | 0.00 99.94% | |
inventory turnover | ||||||||
invested capital | -0.29 - | -0.25 14.04% | -0.19 21.66% | 0.23 216.17% | 0.39 73.03% | 0.47 20.76% | 0.82 74.11% | |
market cap | 609.91M - | 551.53M 9.57% | 609.91M 10.59% | 394.89M 35.26% | 423.83M 7.33% | 381.35M 10.02% | 303.02B 79,359.35% | |
net current asset value | -43.17M - | -89.20M 106.61% | -169.33M 89.83% | 204.48M 220.76% | 100.78M 50.72% | 134.32M 33.29% | 56.29M 58.09% | |
net debt to ebitda | 0.28 - | 0.28 1.92% | 0.78 180.96% | 195.23 24,900.15% | 1.19K 511.25% | -0.13 100.01% | -0.32 144.81% | |
net income per share | -0.49 - | -1.24 149.75% | -2.33 88.66% | 0.07 102.92% | 0.07 3.86% | -0.89 1,357.03% | -0.00 99.85% | |
operating cash flow per share | -0.57 - | -1.06 85.22% | -1.62 53.17% | -3.15 94.27% | -1.65 47.66% | -0.37 77.42% | -0.00 99.73% | |
payables turnover | ||||||||
receivables turnover | 14.34 - | 7.18 49.94% | ||||||
research and ddevelopement to revenue | 6.40 - | 4.38 - | 1.17 73.20% | 2.42 106.58% | ||||
return on tangible assets | -1.06 - | -1.12 6.28% | -0.65 41.63% | 0.01 101.02% | 0.02 149.13% | -0.18 1,206.96% | -0.46 148.88% | |
revenue per share | 0.08 - | 0.00 - | 1.81 360,856.00% | 0.00 99.96% | ||||
roe | 0.59 - | 0.58 1.26% | 0.62 7.05% | 0.01 98.49% | 0.03 201.14% | -0.34 1,310.18% | -1.19 248.87% | |
roic | 0.80 - | 0.73 9.75% | 0.76 4.89% | 0.01 99.11% | 0.02 193.82% | -0.20 1,085.55% | -0.60 204.09% | |
sales general and administrative to revenue | 1.84 - | 1.15 - | 0.29 74.95% | 0.58 100.92% | ||||
shareholders equity per share | -0.84 - | -2.14 152.92% | -3.76 76.23% | 7.28 293.41% | 2.51 65.51% | 2.61 3.87% | 0.00 99.96% | |
stock based compensation to revenue | 0.13 - | 534.73 - | 0.15 99.97% | 0.36 146.27% | ||||
tangible asset value | -40.38M - | -82.27M 103.75% | -155.06M 88.48% | 256.42M 265.37% | 150.66M 41.24% | 182.05M 20.83% | 98.15M 46.08% | |
tangible book value per share | -1.02 - | -2.29 125.32% | -3.90 70.44% | 7.12 282.54% | 2.42 66.02% | 2.53 4.51% | 0.00 99.96% | |
working capital | 8.58M - | 19.61M 128.59% | 105.32M 436.96% | 283.97M 169.62% | 170.54M 39.95% | 244.68M 43.47% | 155.16M 36.59% |
All numbers in (except ratios and percentages)